Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07NPS
|
|||
| Former ID |
DCL000266
|
|||
| Drug Name |
Zarnestra
|
|||
| Synonyms |
JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 3 | [1] | |
| Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.7; ICD-9: 205.1] | Phase 2 | [2] | ||
| Human papillomavirus infection [ICD-11: 1A9Y; ICD-9: 078.1079.4] | Phase 2 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 2 | [2] | ||
| Peripheral T-cell lymphoma [ICD-11: 2A90.C; ICD-10: C84.4; ICD-9: 202.7] | Phase 2 | [2] | ||
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 1/2 | [3] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 1/2 | [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Johnson & Johnson
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H22Cl2N4O
|
|||
| Canonical SMILES |
CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N
|
|||
| InChI |
1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1
|
|||
| InChIKey |
PLHJCIYEEKOWNM-HHHXNRCGSA-N
|
|||
| CAS Number |
CAS 192185-72-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
585649, 832410, 7888511, 10253567, 12015141, 14761666, 17397811, 46234610, 46393532, 50068229, 50070545, 50071176, 50338599, 53786797, 56312114, 56312367, 56312532, 56313495, 57348598, 99437159, 103147494, 103147495, 103215883, 104019153, 113442141, 117464682, 124756405, 124757260, 125164064, 126671591, 126731531, 131480879, 134338923, 135114737, 135727464, 136112251, 136367426, 136367759, 137001831, 137275907, 142561469, 143496162, 152234876, 152258237, 152344258, 160647073, 160849487, 162037607, 162198470, 162809236
|
|||
| ChEBI ID |
CHEBI:141969
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Farnesyl protein transferase (Ftase) | Target Info | Modulator | [4] |
| Geranyltranstransferase (FDPS) | Target Info | Inhibitor | [2] | |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Trans, trans-farnesyl diphosphate biosynthesis | ||||
| Geranylgeranyldiphosphate biosynthesis | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Influenza A | ||||
| HTLV-I infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| Reactome | Cholesterol biosynthesis | |||
| Activation of gene expression by SREBF (SREBP) | ||||
| WikiPathways | Activation of Gene Expression by SREBP (SREBF) | |||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00093990) Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 4 | Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.